miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2–Versican Pathway

Salem, Mohamed A.; O’Brien, Jacob A.; Bernaudo, Stefanie; Shawer, Heba; Ye, Gang; Brkić, Jelena; Amleh, Asma; Vanderhyden, Barbara C.; Refky, Basel; Yang, Burton B.; Krylov, Sergey N.; Peng, Chun

doi:10.1158/0008-5472.can-17-3014

Cited by 90 publications

(83 citation statements)

References 47 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a target gene, FOXA2 has been regulated by various miRNAs, such as miR-1291 and miR-590. 27,28 Consistent with our results, downregulation of FOXA2 has been reported to serve as a tumor suppressor in lung cancer, breast cancer and pancreatic cancer. 18,29,30 In addition, miR-141-3p has been reported to foster cell growth, invasion, and tumorigenesis of cervical cancer by targeting FOXA2.…”

Section: Discussionsupporting

confidence: 90%

<p>MicroRNA-1246 Promotes Melanoma Progression Through Targeting FOXA2</p>

Yu¹,

Yu²,

Sun³

2020

OTT

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

<p>MicroRNA-1246 Promotes Melanoma Progression Through Targeting FOXA2</p>

Yu¹,

Yu²,

Sun³

2020

OTT

View full text Add to dashboard Cite

“…42 Nevertheless, the other study showed that overexpression of miR-320 could promote the invasion and metastasis of ovarian cancer. 45 Zhang et al 14 found that miR-590-3p was downregulated in GEM-resistant T24 cells, unexpectedly, upregulated in our qRT-PCR. For miR-590-3p, it could inhibit cell proliferation, cell migration, and clonogenic activity of head and neck cancer cells.…”

Section: Discussionmentioning

confidence: 57%

Comprehensive analysis of microRNA‐messenger RNA regulatory network in gemcitabine‐resistant bladder cancer cells

Zhang

Chang

Gong

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Chemotherapy is still a standard treatment of unresectable bladder cancer or distant metastases. The chemotherapy resistance always occurs after a period of treatment indicating poor prognosis. The current study aimed to explore the molecular mechanism of chemoresistance in bladder cancer cells. The gene expression profiles of GSE77883, including three untreated T24 cells samples and three gemcitabine‐resistant T24 cells samples, was downloaded from Gene Expression Omnibus database. The screening of differentially expressed genes (DEGs), gene function analysis, and interaction prediction between microRNAs (miRNAs) and DEGs were performed by R software. The protein‐protein interaction (PPI) and miRNA‐DEGs networks were constructed and visualized by Cytoscape software. Then, the small molecules, with potential synergistic or antagonistic effects to gemcitabine resistance, were identified using the Connectivity Map database. Finally, gemcitabine‐resistant T24 cell line was established and key genes were validated by quantitative real‐time polymerase chain reaction (qRT‐PCR). In total, 536 upregulated and 513 downregulated genes were screened and mainly enriched in oxidative stress response and signaling pathways related to extracellular matrix–receptor interaction and focal adhesion. PPI network showed interleukin 6, tumor necrosis factor, kinesin family member 11, and BUB1 mitotic checkpoint serine/threonine kinase B were key genes. The miRNA‐DEGs regulatory networks included 18 miRNAs and 185 DEGs, including miR‐182‐5p, miR‐590‐3p, miR‐320a and serum‐ and glucocorticoid‐regulated kinase 1 (SGK1). Then, the related key genes and miRNAs were confirmed by qRT‐PCR. Furthermore, 81 small molecules with antagonistic or synergistic effect to GEM were screened. We have investigated the molecular mechanisms driving GEM‐resistance in bladder cancer cells that would contribute to the development of chemotherapy for advanced bladder cancer.

show abstract

“…Moreover, FOXA2 is capable of facilitating EMT, inhibiting apoptosis and enhancing colon cancer cell invasion ability. In OV, miR-590-3p can promote growth and metastasis via the FOXA2-Versican pathway (44).…”

Section: Discussionmentioning

confidence: 99%

Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Ovarian Cancer

Wang

Bao

Nie

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer (OV) is the most common gynecological cancer and is a major cause of cancer-related death among women worldwide. Immunotherapy has recently been of great interest, and it has been proven to be an effective treatment strategy. For this reason, the work here attempts to produce a prognostic immune-related gene pair (IRGP) signature to estimate OV patient survival. Methods: The Gene ExpressionOmnibus (GEO) and the Cancer Genome Atlas (TCGA) databases provided the genetic expression profiles and clinical data of OV patients, whose samples were divided into training, validation, and testing sets. The InnateDB database and the least absolute shrinkage and selection operator (LASSO) regression model, were used to build an IRGP signature. The functional enrichment analysis was performed to investigate the biological activities of IRGPs. Then, the correlation between risk scores and clinicopathological parameters was further analyzed. Finally, we compared our signature and four existing signatures for OV. Results: We first identified a 17-IRGP signature significantly associated with survival based on LASSO regression model. The average area under the curve (AUC) values of the training, validation, and all

show abstract

miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2–Versican Pathway

Cited by 90 publications

References 47 publications

<p>MicroRNA-1246 Promotes Melanoma Progression Through Targeting FOXA2</p>

<p>MicroRNA-1246 Promotes Melanoma Progression Through Targeting FOXA2</p>

Comprehensive analysis of microRNA‐messenger RNA regulatory network in gemcitabine‐resistant bladder cancer cells

Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Ovarian Cancer

Contact Info

Product

Resources

About